Asceneuron | Appoints new Board Member
Share this article
Asceneuron Appoints Prominent Healthcare Leader Catherine Moukheibir to its Board of Directors
On 16 July 2021, the Lausanne based clinical stage company, Asceneuron, announced the appointment of Catherine Moukheibir to its Board of Directors. This addition underscores company’s ambition to deliver on the unmet needs of patients living with neurodegenerative diseases.
Catherine is a highly respected healthcare executive with extensive experience over the last 30 years of leadership in finance, capital markets and life sciences. She has previously worked as a Chairman, Non-Executive Director and Chief Executive Officer in the biotech and pharmaceutical sectors, successfully raising private and public capital as well as overseeing several major licensing deals and acquisitions.